Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYRON: ABS-1230 in KCNT1-Related Epilepsy
NCT07600736Phase 2Recruiting
- Sponsor
- Actio Biosciences
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ABS-1230 in KCNT1-related epilepsy, sponsored by Actio Biosciences. Started May 2026; status: recruiting.
02
Drugs
ABS-1230
03
Conditions
KCNT1-related epilepsy
Beyond the preview
Go deeper on NCT07600736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600736.